| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.2 | 2.2 |
| Gross profit | 1.5 | 1.4 |
| Profit before tax | -2.0 | 0.5 |
| Net income | -2.0 | 0.5 |
| EPS (diluted, $ a share) | $-5.81 | $177.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -0.2% |
|---|---|
| Gross margin | 69.5% |
| Operating margin | -92.8% |
10-Q filed with the SEC, NASDAQ: NUWE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nuwellis, Inc.: key numbers
- Share price
- $4.48Close, Nov 16
- Market cap
- $2.42M
- Shares outstanding
- 540.91KLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nuwellis, Inc.
All →Nuwellis Investor Presentation
Nuwellis, Inc. filed an updated corporate investor presentation dated November 17, 2026, to be used for upcoming investor communications and conferences. The presentation highlights the company's Aquadex ultrafiltration technology, its $4.4 billion U.S. market opportunity, and year-to-date revenue growth of 13%.
Nuwellis Financial Results
Nuwellis reported Q3 2026 financial results with net sales of $2.2 million and a 24% improvement in operating loss to $2.1 million. The company highlighted significant gross margin expansion to 69.5% and an 88% year-to-date increase in Aquadex console unit sales, which builds the installed base for future recurring revenue.
- Term
- Q3 2026
“We have made meaningful progress in strengthening Nuwellis both commercially and financially. Year to date, console unit sales have nearly doubled, expanding our installed base and creating a larger opportunity to grow recurring circuit revenue. Although our third quarter faced a tough comparison against the prior-year period when we fulfilled a significant backorder, the underlying momentum in our business remains strong, as evidenced by the growth in our pediatric segment.”
Mike McCormick, Nuwellis President and Chief Executive
Nuwellis Reverse Stock Split
Nuwellis, Inc. has announced a 1-for-9 reverse stock split of its issued and outstanding common stock, effective October 26, 2026. The split-adjusted shares will begin trading on the Nasdaq Capital Market under the existing symbol 'NUWE' on October 27, 2026. This action consolidates every nine shares into one share to adjust the company's capital structure.